scholarly journals Direct healthcare costs associated with management of asthma: comparison of two treatment regimens in Indonesia, Thailand and Vietnam

2021 ◽  
pp. 1-8
Author(s):  
Bhumika Aggarwal ◽  
Paul W. Jones ◽  
Faisal Yunus ◽  
Le Thi Tuyet Lan ◽  
Watchara Boonsawat ◽  
...  
Keyword(s):  
Healthcare Costs ◽  
Treatment Regimens ◽  
Direct Healthcare Costs

scholarly journals Frailty Phenotype and Healthcare Costs in Women in Late Life: The SOF study

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 778-778
Author(s):  
Lisa Langsetmo ◽  
Allyson Kats ◽  
John Schousboe ◽  
Tien Vo ◽  
Brent Taylor ◽  
...  
Keyword(s):  
Healthcare Costs ◽  
Functional Limitations ◽  
Late Life ◽  
Cost Ratio ◽  
Deficit Accumulation ◽  
Frailty Phenotype ◽  
Medicare Claims ◽  
Accumulation Index ◽  
Direct Healthcare Costs ◽  
Frailty Indicator

Abstract We used data from 1324 women (mean age 83) at the 2002-2004 exam linked with their Medicare claims to determine the association of the frailty phenotype with healthcare costs. The frailty phenotype was categorized as robust, pre-frail or frail. Multimorbidity and a frailty indicator (approximating the deficit accumulation index) were derived from claims. Functional limitations were assessed by asking about difficulty performing IADL. Total direct healthcare costs were ascertained during 36 months following the exam. Compared with robust, pre-frailty and frailty were associated with higher costs after accounting for demographics, multimorbidity, functional limitations and the frailty indicator (cost ratio 1.37 [1.10-1.71] among pre-frail and 1.63 [1.28-2.08] among frail). Discrimination of high-cost (top decile) women was improved by adding the phenotype and functional limitations to a model containing demographics and the claims-based measures. Findings suggest that assessment of the phenotype may improve identification of individuals at higher risk of costly care.

MO545INSIDE ANEMIA OF CKD: ESTIMATING THE IMPACT OF POLICY INTERVENTIONS ON ANAEMIA OF CKD IN THE USA BY MICROSIMULATION MODELLING

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Lise Retat ◽  
Laura Webber ◽  
Juan Jose Garcia Sanchez ◽  
Claudia Cabrera ◽  
Susan Grandy ◽  
...  
Keyword(s):  
Healthcare Costs ◽  
Severe Anaemia ◽  
Service Planning ◽  
Microsimulation Model ◽  
Model Framework ◽  
The Us ◽  
The Usa ◽  
Direct Healthcare Costs ◽  
The Impact ◽  
Intervention Scenario

Abstract Background and Aims Anaemia is a common complication in patients with chronic kidney disease (CKD) and is associated with increased mortality, cardiovascular complications, reduced quality of life and increased use of healthcare resources. Mathematical modelling based on robust epidemiological and clinical data is a useful approach for predicting the future burden of disease and the impact of different intervention scenarios; this is important for health service planning. This analysis uses a microsimulation model, Inside ANEMIA of CKD, to predict the effects of a hypothetical intervention scenario that reduces the prevalence of anaemia of CKD on related healthcare costs in the USA from 2020 to 2025. Method A virtual cohort representing the US population was created within the Inside ANEMIA of CKD microsimulation model framework using demographics and epidemiological data drawn from the US Census Bureau, the Centers for Disease Control and Prevention, and the National Health and Nutrition Examination Survey. In the cohort, virtual individuals were ascribed an age–sex-stratified CKD status (defined by estimated glomerular filtration rate and albuminuria levels, as per international guidelines) and anaemia status (defined by haemoglobin level as mild, moderate or severe, as per WHO criteria) based on US prevalence data. Key comorbidities (type 2 diabetes, heart failure and hypertension) were also assigned, reflecting US-specific population statistics. Healthcare costs related to CKD and anaemia of CKD were taken from the published literature. The study modelled the effects on healthcare costs of a hypothetical intervention scenario in which the prevalence of moderate and severe anaemia is reduced by 20% per year from 2020 to 2025 compared with no intervention (baseline). In each scenario (i.e. intervention or baseline), the modelling analysis estimated healthcare costs related to CKD and anaemia (including inpatient, outpatient, pharmacy costs) for patients with moderate or severe anaemia of CKD. The model did not adjust for the potential costs of the intervention. Results Preliminary results predict that, with the hypothetical intervention, there could be 1.40 million fewer patients with moderate or severe anaemia of CKD in the USA in 2025 compared with no intervention (1.45 million versus 2.85 million). This represents a 49% reduction in cases of moderate or severe anaemia of CKD in 2025 with the intervention versus no intervention. The intervention is projected to lead to a reduction of approximately US$18 billion in annual direct healthcare costs in 2025 for patients with moderate or severe anaemia of CKD compared with no intervention (US$26 billion versus US$44 billion). Conclusion The Inside ANEMIA of CKD microsimulation model predicts that a hypothetical intervention which reduces the prevalence of moderate and severe anaemia of CKD would reduce direct healthcare costs. This suggests that interventions effective at reducing the prevalence of anaemia of CKD would help to reduce the economic burden on healthcare services.

scholarly journals Direct costs of overdiagnosed asthma: a longitudinal, population-based cohort study in British Columbia, Canada

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e031306 ◽  
Author(s):  
Bryan Ng ◽  
Mohsen Sadatsafavi ◽  
Abdollah Safari ◽  
J Mark FitzGerald ◽  
Kate M Johnson
Keyword(s):  
Cohort Study ◽  
Resource Use ◽  
Healthcare Costs ◽  
Challenge Test ◽  
Medication Use ◽  
Population Based ◽  
Methacholine Challenge ◽  
Physician Visits ◽  
Direct Healthcare Costs ◽  
Physician Diagnosis

ObjectivesA current diagnosis of asthma cannot be objectively confirmed in many patients with physician-diagnosed asthma. Estimates of resource use in overdiagnosed cases of asthma are necessary to measure the burden of overdiagnosis and to evaluate strategies to reduce this burden. We assessed differences in asthma-related healthcare resource use between patients with a confirmed asthma diagnosis and those with asthma ruled out.DesignPopulation-based, prospective cohort study.SettingParticipants were recruited through random-digit dialling of both landlines and mobile phones in the province of British Columbia, Canada.ParticipantsWe included 345 individuals ≥12 years of age with a self-reported physician diagnosis of asthma. The diagnosis of asthma was reassessed at the end of 12 months of follow-up using a structured algorithm, which included a bronchodilator reversibility test, methacholine challenge test, and if necessary medication tapering and a second methacholine challenge test.Primary and secondary outcome measuresSelf-reported annual asthma-related direct healthcare costs (2017 Canadian dollars), outpatient physician visits and medication use from the perspective of the Canadian healthcare system.ResultsAsthma was ruled out in 86 (24.9%) participants. The average annual asthma-related direct healthcare costs for participants with confirmed asthma were $C497.9 (SD $C677.9) and for participants with asthma ruled out, $C307.7 (SD $C424.1). In the adjusted analyses, a confirmed diagnosis was associated with higher direct healthcare costs (relative ratio (RR)=1.60, 95% CI 1.14 to 2.22), increased rate of specialist visits (RR=2.41, 95% CI 1.05 to 5.40) and reliever medication use (RR=1.62, 95% CI 1.09 to 2.35), but not primary care physician visits (p=0.10) or controller medication use (p=0.11).ConclusionsA quarter of individuals with a physician diagnosis of asthma did not have asthma after objective re-evaluation. These participants still consumed a significant amount of asthma-related healthcare resources. The population-level economic burden of asthma overdiagnosis could be substantial.

Direct Healthcare Costs of Osteoporosis-Related Fractures in Managed Care Patients Receiving Pharmacological Osteoporosis Therapy

2012 ◽  
Vol 10 (3) ◽  
pp. 163-173 ◽  
Author(s):  
Hema N. Viswanathan ◽  
Jeffrey R. Curtis ◽  
Jingbo Yu ◽  
Jeffrey White ◽  
Bradley S. Stolshek ◽  
...  
Keyword(s):  
Managed Care ◽  
Healthcare Costs ◽  
Osteoporosis Therapy ◽  
Direct Healthcare Costs

scholarly journals The direct healthcare costs associated with psychological distress and major depression: A population-based cohort study in Ontario, Canada

PLoS ONE ◽  
2017 ◽  
Vol 12 (9) ◽  
pp. e0184268 ◽  
Author(s):  
Maria Chiu ◽  
Michael Lebenbaum ◽  
Joyce Cheng ◽  
Claire de Oliveira ◽  
Paul Kurdyak
Keyword(s):  
Cohort Study ◽  
Psychological Distress ◽  
Major Depression ◽  
Healthcare Costs ◽  
Population Based ◽  
Direct Healthcare Costs

scholarly journals Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

2020 ◽  
Vol 9 (8) ◽  
pp. 537-551 ◽  
Author(s):  
Lucy Gilbert ◽  
Agnihotram V Ramanakumar ◽  
Maria Carolina Festa ◽  
Kris Jardon ◽  
Xing Zeng ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Healthcare Costs ◽  
Median Overall Survival ◽  
Cytotoxic Chemotherapy ◽  
High Grade ◽  
Chemotherapy Drugs ◽  
Tertiary Center ◽  
Direct Healthcare Costs ◽  
First Relapse ◽  
Mean Cost

Aim: To describe the direct healthcare costs associated with repeated cytotoxic chemotherapy treatments for recurrent high-grade serous cancer (HGSC) of the ovaries. Patients & methods: Retrospective review of 66 women with recurrent stage III/IV HGSC ovarian cancer treated with repeated lines of cytotoxic chemotherapy in a Canadian University Tertiary Center. Results: Mean cost of treatment of first relapse was CAD$52,227 increasing by 38% for two, and 86% for three or more relapses with median overall survival of 36.0, 50.7 and 42.8 months, respectively. In-hospital care accounted for 71% and chemotherapy drugs accounted for 17% of the total costs. Conclusion: After the third relapse of HGSC, cytotoxic chemotherapy did not prolong survival but was associated with substantially increased healthcare costs.

scholarly journals Health service utilization and direct healthcare costs associated with obesity in older adult population in Ghana

2019 ◽  
Vol 35 (2) ◽  
pp. 199-209 ◽  
Author(s):  
Stella T Lartey ◽  
Barbara de Graaff ◽  
Costan G Magnussen ◽  
Godfred O Boateng ◽  
Moses Aikins ◽  
...  
Keyword(s):  
Older Adults ◽  
Chronic Disease ◽  
Health Service ◽  
Older Adult ◽  
Service Utilization ◽  
Healthcare Costs ◽  
Health Service Utilization ◽  
Normal Weight ◽  
Overweight And Obesity ◽  
Direct Healthcare Costs

Abstract Obesity is a major risk factor for many chronic diseases and disabilities, with severe implications on morbidity and mortality among older adults. With an increasing prevalence of obesity among older adults in Ghana, it has become necessary to develop cost-effective strategies for its management and prevention. However, developing such strategies is challenging as body mass index (BMI)-specific utilization and costs required for cost-effectiveness analysis are not available in this population. Therefore, this study examines the associations between health services utilization as well as direct healthcare costs and overweight (BMI ≥25.00 and <30.00 kg/m2) and obesity (BMI ≥30.00 kg/m2) among older adults in Ghana. Data were used from a nationally representative, multistage sample of 3350 people aged 50+ years from the World Health Organization’s Study on global AGEing and adult health (WHO-SAGE; 2014/15). Health service utilization was measured by the number of health facility visits over a 12-month period. Direct costs (2017 US dollars) included out-of-pocket payments and the National Health Insurance Scheme (NHIS) claims. Associations between utilization and BMI were examined using multivariable zero-inflated negative binomial regressions; and between costs and BMI using multivariable two-part regressions. Twenty-three percent were overweight and 13% were obese. Compared with normal-weight participants, overweight and obesity were associated with 75% and 159% more inpatient admissions, respectively. Obesity was also associated with 53% additional outpatient visits. One in five of the overweight and obese population had at least one chronic disease, and having chronic disease was associated with increased outpatient utilization. The average per person total costs for overweight was $78 and obesity was $132 compared with $35 for normal weight. The NHIS bore approximately 60% of the average total costs per person expended in 2014/15. Overweight and obese groups had significantly higher total direct healthcare costs burden of $121 million compared with $64 million for normal weight in the entire older adult Ghanaian population. Compared with normal weight, the total costs per person associated with overweight increased by 73% and more than doubled for obesity. Even though the total prevalence of overweight and obesity was about half of that of normal weight, the sum of their cost burden was almost doubled. Implementing weight reduction measures could reduce health service utilization and costs in this population.

Sign in / Sign up

Export Citation Format

Share Document